Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)

July 20, 2018 updated by: GlaxoSmithKline

Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level

This is a multi-centered, randomized, placebo-controlled, double-blind, parallel group, trial evaluating 2 doses of mepolizumab against placebo given every 4 weeks through subcutaneous (SC) injection. In severe COPD subjects, sputum eosinophils levels are elevated to similar levels as those seen in severe asthmatics. It is hypothesized that the reduction of eosinophils with mepolizumab in COPD subjects would translate into a reduction of COPD exacerbations. The study will evaluate the efficacy and safety of mepolizumab, in subjects who are at or above the baseline blood eosinophil count of at least 150 cells/microliters who exacerbate despite regular use of maximal tolerated therapy, appropriate for severe COPD subjects, in the 12 months prior to study start. In total, 660 subjects will be randomized in 1:1:1 ratio to receive mepolizumab 300 mg, mepolizumab 100mg, or placebo administered SC. The total duration of subject participation will be approximately 62 weeks, consisting of a 1 to 2 week screening period, 52-week treatment period and 8-week follow-up period.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

674

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Berazategui, Argentina, 1886
        • GSK Investigational Site
      • Buenos Aires, Argentina, C1425BEN
        • GSK Investigational Site
      • Ciudad Autónoma de Buenos Aires, Argentina, C1121ABE
        • GSK Investigational Site
      • Mendoza, Argentina, M5500CCG
        • GSK Investigational Site
      • Mendoza, Argentina, 5500
        • GSK Investigational Site
    • Buenos Aires
      • Bahía Blanca, Buenos Aires, Argentina, B8000AAK
        • GSK Investigational Site
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1414AIF
        • GSK Investigational Site
      • La Plata, Buenos Aires, Argentina, 1900
        • GSK Investigational Site
      • Mar del Plata, Buenos Aires, Argentina, 7600
        • GSK Investigational Site
    • New South Wales
      • Coffs Harbour, New South Wales, Australia, 2450
        • GSK Investigational Site
      • Maroubra, New South Wales, Australia, 2035
        • GSK Investigational Site
    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • GSK Investigational Site
    • Nova Scotia
      • Truro, Nova Scotia, Canada, B2N 1L2
        • GSK Investigational Site
    • Ontario
      • Burlington, Ontario, Canada, L7N 3V2
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M5T 3A9
        • GSK Investigational Site
      • Windsor, Ontario, Canada, N8X 5A6
        • GSK Investigational Site
    • Quebec
      • St-Charles-Borromée, Quebec, Canada, J6E 2B4
        • GSK Investigational Site
      • Trois Rivieres, Quebec, Canada, G8T 7A1
        • GSK Investigational Site
      • Santiago, Chile, 8380453
        • GSK Investigational Site
      • Santiago, Chile, 7500698
        • GSK Investigational Site
    • Región Del Maule
      • Talca, Región Del Maule, Chile, 3460001
        • GSK Investigational Site
    • Región Metro De Santiago
      • Santiago, Región Metro De Santiago, Chile, 7500692
        • GSK Investigational Site
      • Santiago, Región Metro De Santiago, Chile, 7860406
        • GSK Investigational Site
      • Santiago, Región Metro De Santiago, Chile, 8242238
        • GSK Investigational Site
    • Valparaíso
      • Valparaiso, Valparaíso, Chile, 2341131
        • GSK Investigational Site
      • Aarhus C, Denmark, 8000
        • GSK Investigational Site
      • Hvidovre, Denmark, 2650
        • GSK Investigational Site
      • Kobenhavn NV, Denmark, 2400
        • GSK Investigational Site
      • Odense C, Denmark, 5000
        • GSK Investigational Site
      • Berlin, Germany, 10717
        • GSK Investigational Site
      • Berlin, Germany, 12203
        • GSK Investigational Site
      • Berlin, Germany, 12157
        • GSK Investigational Site
      • Hamburg, Germany, 22299
        • GSK Investigational Site
    • Baden-Wuerttemberg
      • Stuttgart, Baden-Wuerttemberg, Germany, 70378
        • GSK Investigational Site
    • Brandenburg
      • Ruedersdorf, Brandenburg, Germany, 15562
        • GSK Investigational Site
    • Hessen
      • Frankfurt, Hessen, Germany, 60596
        • GSK Investigational Site
      • Frankfurt, Hessen, Germany, 60389
        • GSK Investigational Site
      • Neu-Isenburg, Hessen, Germany, 63263
        • GSK Investigational Site
    • Niedersachsen
      • Hannover, Niedersachsen, Germany, 30173
        • GSK Investigational Site
    • Rheinland-Pfalz
      • Mainz, Rheinland-Pfalz, Germany, 55131
        • GSK Investigational Site
    • Sachsen
      • Dresden, Sachsen, Germany, 01307
        • GSK Investigational Site
      • Leipzig, Sachsen, Germany, 04357
        • GSK Investigational Site
    • Sachsen-Anhalt
      • Magdeburg, Sachsen-Anhalt, Germany, 39112
        • GSK Investigational Site
    • Schleswig-Holstein
      • Luebeck, Schleswig-Holstein, Germany, 23552
        • GSK Investigational Site
      • Ehime, Japan, 791-0281
        • GSK Investigational Site
      • Fukui, Japan, 910-1193
        • GSK Investigational Site
      • Fukuoka, Japan, 811-1394
        • GSK Investigational Site
      • Fukushima, Japan, 960-1295
        • GSK Investigational Site
      • Gifu, Japan, 509-6134
        • GSK Investigational Site
      • Hiroshima, Japan, 722-8503
        • GSK Investigational Site
      • Hiroshima, Japan, 734-8530
        • GSK Investigational Site
      • Hokkaido, Japan, 053-8506
        • GSK Investigational Site
      • Hyogo, Japan, 650-0047
        • GSK Investigational Site
      • Kagawa, Japan, 762-8550
        • GSK Investigational Site
      • Kanagawa, Japan, 227-8501
        • GSK Investigational Site
      • Kumamoto, Japan, 861-1196
        • GSK Investigational Site
      • Mie, Japan, 515-8544
        • GSK Investigational Site
      • Miyagi, Japan, 980-8574
        • GSK Investigational Site
      • Miyagi, Japan, 986-8522
        • GSK Investigational Site
      • Miyagi, Japan, 983-8520
        • GSK Investigational Site
      • Oita, Japan, 876-0813
        • GSK Investigational Site
      • Okayama, Japan, 702-8055
        • GSK Investigational Site
      • Okayama, Japan, 711-0921
        • GSK Investigational Site
      • Okinawa, Japan, 901-2121
        • GSK Investigational Site
      • Osaka, Japan, 589-8511
        • GSK Investigational Site
      • Osaka, Japan, 591-8555
        • GSK Investigational Site
      • Osaka, Japan, 573-0153
        • GSK Investigational Site
      • Shimane, Japan, 693-8501
        • GSK Investigational Site
      • Shizuoka, Japan, 436-0022
        • GSK Investigational Site
      • Shizuoka, Japan, 438-8550
        • GSK Investigational Site
      • Tokyo, Japan, 103-0027
        • GSK Investigational Site
      • Tokyo, Japan, 142-8666
        • GSK Investigational Site
      • Tokyo, Japan, 104-8560
        • GSK Investigational Site
      • Tokyo, Japan, 136-0075
        • GSK Investigational Site
      • Tokyo, Japan, 204-8585
        • GSK Investigational Site
      • Tokyo, Japan, 152-0021
        • GSK Investigational Site
      • Anyang-Si Gyeonggi-do, Korea, Republic of, 431-070
        • GSK Investigational Site
      • Bucheon city, Gyenggi-do, Korea, Republic of, 420-767
        • GSK Investigational Site
      • Busan, Korea, Republic of, 602-715
        • GSK Investigational Site
      • Cheongju, Chungcheongbuk-do, Korea, Republic of, 361-711
        • GSK Investigational Site
      • Daegu, Korea, Republic of, 705-703
        • GSK Investigational Site
      • Incheon, Korea, Republic of, 403-720
        • GSK Investigational Site
      • Jeonju-si, Korea, Republic of, 561-712
        • GSK Investigational Site
      • Seoul, Korea, Republic of, 138-736
        • GSK Investigational Site
      • Seoul, Korea, Republic of, 140-743
        • GSK Investigational Site
      • Seoul, Korea, Republic of, 130-709
        • GSK Investigational Site
      • Seoul, Korea, Republic of
        • GSK Investigational Site
      • Seoul, Korea, Republic of, 130-872
        • GSK Investigational Site
      • Seoul,, Korea, Republic of, 120-752
        • GSK Investigational Site
      • Wonju-si, Kanwon-do, Korea, Republic of, 220-701
        • GSK Investigational Site
      • Almelo, Netherlands, 7609 PP
        • GSK Investigational Site
      • Breda, Netherlands, 4818 CK
        • GSK Investigational Site
      • Den Bosch, Netherlands, 5223 GZ
        • GSK Investigational Site
      • Groningen, Netherlands, 9713 GZ
        • GSK Investigational Site
      • Hoofddorp, Netherlands, 2134 TM
        • GSK Investigational Site
      • Horn, Netherlands, 6085 NM
        • GSK Investigational Site
      • Leiden, Netherlands, 2333 ZA
        • GSK Investigational Site
      • Sittard-geleen, Netherlands, 6162 BG
        • GSK Investigational Site
      • Utrecht, Netherlands, 3584 CX
        • GSK Investigational Site
      • Zutphen, Netherlands, 7207 AE
        • GSK Investigational Site
      • Bucharest, Romania, 050159
        • GSK Investigational Site
      • Bucharest, Romania, 020125
        • GSK Investigational Site
      • Cluj Napoca, Romania, 400371
        • GSK Investigational Site
      • Cluj-Napoca, Romania, 400371
        • GSK Investigational Site
      • Codlea, Romania, 505100
        • GSK Investigational Site
      • Craiova, Romania, 200642
        • GSK Investigational Site
      • Focsani, Romania, 620043
        • GSK Investigational Site
      • Iasi, Romania, 700115
        • GSK Investigational Site
      • Pitesti, Romania, 110084
        • GSK Investigational Site
      • Ploiesti, Romania, 100024
        • GSK Investigational Site
      • Timisoara, Romania, 300310
        • GSK Investigational Site
      • Humenne, Slovakia, 066 01
        • GSK Investigational Site
      • Poprad, Slovakia, 058 01
        • GSK Investigational Site
      • Sala, Slovakia, 927 01
        • GSK Investigational Site
      • Spisska Nova Ves, Slovakia, 052 01
        • GSK Investigational Site
      • Vrable, Slovakia, 952 01
        • GSK Investigational Site
      • Kaohsiung, Taiwan, 824
        • GSK Investigational Site
      • Taichung, Taiwan, 404
        • GSK Investigational Site
      • Taipei, Taiwan
        • GSK Investigational Site
      • Taipei, Taiwan, 220
        • GSK Investigational Site
      • Tau-Yuan County, Taiwan, 333
        • GSK Investigational Site
      • Dnipropetrovsk, Ukraine, 49051
        • GSK Investigational Site
      • Kharkiv, Ukraine, 61124
        • GSK Investigational Site
      • Kharkiv, Ukraine, 61035
        • GSK Investigational Site
      • Kiev, Ukraine, 03680
        • GSK Investigational Site
      • Kyiv, Ukraine, 03680
        • GSK Investigational Site
      • Kyiv, Ukraine, 03038
        • GSK Investigational Site
      • Mykolayiv, Ukraine, 54003
        • GSK Investigational Site
      • Vinnytsia, Ukraine, 21018
        • GSK Investigational Site
      • Bradford, United Kingdom, BD9 6RJ
        • GSK Investigational Site
      • Cambridge, United Kingdom, CB2 0QQ
        • GSK Investigational Site
      • Oxford, United Kingdom, OX3 7LE
        • GSK Investigational Site
      • Plymouth, United Kingdom, PL6 8DH
        • GSK Investigational Site
      • Sheffield, United Kingdom, S5 7AU
        • GSK Investigational Site
      • Stevenage, United Kingdom, SG1 4AB
        • GSK Investigational Site
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • GSK Investigational Site
      • Mobile, Alabama, United States, 36608
        • GSK Investigational Site
    • California
      • Riverside, California, United States, 92506
        • GSK Investigational Site
      • Upland, California, United States, 91786
        • GSK Investigational Site
    • Colorado
      • Broomfield, Colorado, United States, 80023
        • GSK Investigational Site
    • Connecticut
      • Stamford, Connecticut, United States, 06902
        • GSK Investigational Site
    • Florida
      • Boynton Beach, Florida, United States, 33436
        • GSK Investigational Site
      • DeLand, Florida, United States, 32720
        • GSK Investigational Site
      • Edgewater, Florida, United States, 32132
        • GSK Investigational Site
      • Gainesville, Florida, United States, 32608
        • GSK Investigational Site
      • Orlando, Florida, United States, 32825
        • GSK Investigational Site
      • Saint Petersburg, Florida, United States, 33704
        • GSK Investigational Site
    • Georgia
      • Adairsville, Georgia, United States, 30103
        • GSK Investigational Site
      • Duluth, Georgia, United States, 30096
        • GSK Investigational Site
      • Woodstock, Georgia, United States, 30189
        • GSK Investigational Site
    • Idaho
      • Coeur d'Alene, Idaho, United States, 83814
        • GSK Investigational Site
    • Kentucky
      • Bowling Green, Kentucky, United States, 42101
        • GSK Investigational Site
    • New Mexico
      • Albuquerque, New Mexico, United States, 87108
        • GSK Investigational Site
    • North Carolina
      • Charlotte, North Carolina, United States, 28207
        • GSK Investigational Site
      • Gastonia, North Carolina, United States, 28054
        • GSK Investigational Site
      • Huntersville, North Carolina, United States, 28078
        • GSK Investigational Site
    • Ohio
      • Columbus, Ohio, United States, 43213
        • GSK Investigational Site
    • Oregon
      • Portland, Oregon, United States, 97220
        • GSK Investigational Site
    • Pennsylvania
      • Hershey, Pennsylvania, United States, 17033
        • GSK Investigational Site
      • Oaks, Pennsylvania, United States, 19456
        • GSK Investigational Site
      • Philadelphia, Pennsylvania, United States, 19140
        • GSK Investigational Site
    • South Carolina
      • Charleston, South Carolina, United States, 29406-7108
        • GSK Investigational Site
      • Easley, South Carolina, United States, 29640
        • GSK Investigational Site
      • Greenville, South Carolina, United States, 29615
        • GSK Investigational Site
      • Mount Pleasant, South Carolina, United States, 29464
        • GSK Investigational Site
      • Rock Hill, South Carolina, United States, 29732
        • GSK Investigational Site
    • Texas
      • Fort Worth, Texas, United States, 76104
        • GSK Investigational Site
    • Virginia
      • Richmond, Virginia, United States, 23249
        • GSK Investigational Site
      • Richmond, Virginia, United States, 23225
        • GSK Investigational Site
    • West Virginia
      • Morgantown, West Virginia, United States, 26505
        • GSK Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • COPD diagnosis: Subjects with a clinically documented history of COPD for at least 1 year in accordance with the following definition by the American Thoracic Society/European Respiratory Society
  • Severity of COPD: Subjects must present with the following: a measured pre and post-salbutamol Forced expiratory volume in one second/ Forced vital capacity (FEV1/FVC) ratio of <0.70 at Visit 1 to confirm the diagnosis of COPD; a measured post-salbutamol FEV1> 20 percent and <=80 percent of predicted normal values calculated using National Health and Nutrition Examination Survey (NHANES) III reference equations at Visit 1
  • History of exacerbations: A well documented history (e.g., medical record verification) in the 12 months prior to Visit 1 of ; at least two moderate COPD exacerbations. Moderate is defined as the use of systemic corticosteroids (intramuscular (IM), intravenous, or oral) and/or treatment with antibiotics or; at least one severe COPD exacerbation. Severe is defined as having required hospitalization. Note: At least one exacerbation must have occurred while the subject was taking Inhaled corticosteroid (ICS) plus long acting beta2-agonist (LABA) plus long acting muscarinic antagonist (LAMA). Prior use of antibiotics alone does not qualify as a moderate exacerbation unless the use was specifically for the treatment of worsening symptoms of COPD.
  • Concomitant COPD therapy: A well documented requirement for optimized standard of care background therapy that includes Inhaled corticosteroid (ICS) plus 2 additional COPD medications (i.e., triple therapy) for the 12 months prior to Visit 1 and meets the following criteria: Immediately prior to Visit 1, minimum of 3 months of use of an; Inhaled corticosteroid at a dose >= 500 micrograms (mcg)/day fluticasone propionate dose equivalent plus; LABA and LAMA.

For subjects who are not continually maintained on ICS plus LABA plus LAMA for the entire 12 months prior to Visit 1 use of following is allowed (but not in the 3 months immediately prior to Visit 1); inhaled corticosteroid at a dose >=500 mcg/day fluticasone propionate dose equivalent plus; a LABA or a LAMA and; use of at least one other class of COPD medication (i.e., phosphodiesterase-4-inhibitors, methylxanthines, or a combination of short acting beta2-agonist and short acting muscarinic antagonist).

  • Informed Consent: Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Subjects must be able to read, comprehend, and write at a level sufficient to complete study related materials.
  • Gender: Male or Eligible Female; To be eligible for entry into the study females of child bearing potential must commit to consistent and correct use of an acceptable method of birth control from the time of consent, for the duration of the trial, and for 4 months after last study drug administration.
  • Age: At least 40 years of age at Visit 1
  • Smoking status: Subject with confirmed COPD are eligible to participate independent of their smoking status and smoking history, i.e. current smokers, never smokers or ex-smokers can be enrolled into the study. Current smokers are defined as those with a history of cigarette smoking of >=10 pack-years [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Former smokers are defined as those who meet the definition of a current smoker but have stopped smoking for at least 6 months prior to Visit 1. Never smokers are those that do not meet the definition of a current or former smoker.
  • French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion Criteria:

  • Subjects with Asthma: Current and Former Smokers: Subjects with a current diagnosis of asthma (those with a prior history are eligible if they meet inclusion criteria for a current diagnosis of COPD); Never-Smokers: Subjects with any history of asthma.
  • Other respiratory disorders: The investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease. Subjects with alpha1-antitrypsin deficiency as the underlying cause of COPD are excluded. Also, excluded are subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases. Subjects are also excluded if maintenance use of bi-level positive airway pressure is required for the treatment of respiratory disorder.
  • COPD stability: Subjects with pneumonia, exacerbation, lower respiratory infection within the 4 weeks prior to Visit 1.
  • Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Visit 1.
  • Pulmonary rehabilitation program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.
  • Oxygen: Subjects receiving treatment with oxygen more than 4.0 liters/minute (L/min). While breathing supplemental oxygen, subjects should demonstrate an oxyhemoglobin saturation greater than or equal to 89 percent.
  • 12-lead Electrocardiography (ECG) finding: An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1, if considered to be clinically significant by the Investigator. 12-lead ECGs will be over-read by a centralized independent cardiologist to assist in consistent evaluation of subject eligibility. Results from the 12-lead ECG over-read must be received prior to assessing eligibility at Visit 2.
  • Unstable or life threatening cardiac disease: Subjects with any of the following would be excluded: Myocardial infarction or unstable angina in the last 6 months ; Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months ; New York Heart Association (NYHA) Class IV Heart failure
  • Other diseases/abnormalities: Subjects with (historical or) current evidence of clinically significant, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • Eosinophilic disease: Subjects with other conditions that could lead to elevated eosinophils such as Hypereosinophilic syndromes including Eosinophilic Granulomatosis with Polyangiitis (EGPA, also known as Churg-Strauss Syndrome), or Eosinophilic Esophagitis.
  • Parasitic infection: Subjects with a pre-existing helminthes infestation within 6 months prior to Visit 1 are also excluded.
  • Malignancy: A current malignancy or previous history of cancer in remission for less than 12 months prior to Visit 1 (Subjects that had localized carcinoma of the skin or cervix which was resected for cure will not be excluded). South Korea subjects with a diagnosis of malignancy within 5 years of Visit 1 are excluded.
  • Immunodeficiency: A known immunodeficiency (e.g. human immunodeficiency virus HIV), other than that explained by the use of corticosteroids taken for COPD.
  • Liver disease: Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, and known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Chronic stable hepatitis B and C are acceptable if subject otherwise meets entry criteria (e.g., presence of hepatitis B surface antigen or positive hepatitis C test result within 3 months of screening)
  • Monoclonal antibodies: Subjects who have received any monoclonal antibody within 5 half-lives of Visit 1.
  • Investigational medications: Subjects who have received an investigational drug within 30 days of Visit 1, or within 5 drug half-lives of the investigational drug, whichever is longer (this also includes investigational formulations of a marketed product).
  • Hypersensitivity: Subjects with a known allergy or intolerance to another monoclonal antibody or biologic including history of anaphylaxis to another biologic
  • Inability to read: In the opinion of the investigator, any subject who is unable to read and/or would not be able to complete study related materials.
  • Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
  • Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.
  • Drug or alcohol abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.
  • Previous participation: Subjects who have previously participated in any study of mepolizumab.
  • Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study.

Randomization Criteria

In order to be randomized to study drug the subject must meet the following randomization criteria at Visit 2:

  • Blood eosinophils: Documented elevated peripheral blood eosinophil count of >=300 cells/microliter within the past 12 months prior to Visit 1; OR A peripheral baseline blood eosinophil count of >=150 cells/microliter from haematology conducted at Visit 1
  • Electronic Diary Compliance: Compliance with completion of the eDiary defined as completion of all questions on 5 or more days out of the 7 days immediately preceding Visit 2.
  • 12-lead ECG: No evidence of an abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1 as indicated on the over-read provided by the centralized independent cardiologist. Subjects with a QT interval corrected with Fridericia's formulas (QTcF)>=450 msec are not eligible. For subjects with a QRS interval >=120msec, those with QTcF>=480 msec are not eligible. Specific ECG findings that preclude subject eligibility are listed in the protocol.
  • Abnormal chest X-ray (or Computerized Tomography [CT] scan): No chest X-ray (or CT scan) that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. If a chest X-ray or CT scan is not available within 6 months prior to Visit 1, then a chest X-ray must be taken at Visit 1 and the results reviewed prior to randomization. For sites in Germany: If a chest X-ray (or CT scan) within 6 months prior to Screening (Visit 1) is not available, the subject will not be eligible for the study.
  • Laboratory abnormality: No evidence of clinically significant abnormality in the haematological, biochemical, or urinalysis screen at Visit 1, as judged by the investigator.
  • Hepatitis B: Subjects who are HBsAg positive or HBcAb positive must not have a HBV DNA level >=2000 International Units (IU)/millilitre (mL).
  • Liver function test: Subjects must meet the following based on results from sample taken at Visit 1: Alanine aminotransferase (ALT) <2x ULN (upper limit of normal); Alkaline Phosphatase (Alk Phos) <=2x ULN; Bilirubin <=1.5x ULN (isolated bilirubin>1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent)
  • Pregnancy: No subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Arm 1
Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
EXPERIMENTAL: Arm 2
Each subject will receive 300 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
EXPERIMENTAL: Arm 3
Each subject will receive placebo (0.9percent sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) their baseline standard of care COPD medication
Sterile 0.9percent sodium chloride solution

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of Moderate or Severe Exacerbations
Time Frame: From randomization to Week 52
Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (>=24 hours) or result in death. Moderate and severe exacerbations occurring from the start of investigational product (IP) up to the Week 52 visit, including exacerbations reported after early discontinuation from IP by participants who remained in the study, were included in the analysis. The analysis was performed on the modified intent-to-treat (mITT) Population (all randomized participants who received at least one dose of study treatment).
From randomization to Week 52

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to First Moderate/Severe Exacerbation
Time Frame: From randomization to Week 52
Kaplan Meier estimates of the probability of a moderate or severe exacerbation are expressed as the percentage of participants with an exacerbation over time (by Week 8, 16, 24, 32, 40, 48, 52). Analysis of time to first moderate/severe exacerbation was performed on the mITT population and included exacerbations reported on-treatment and those reported after early discontinuation from IP by participants who remained in the study.
From randomization to Week 52
Rate of COPD Exacerbations Requiring Emergency Department (ED) Visits and/or Hospitalizations (Hosp)
Time Frame: From randomization to Week 52
COPD exacerbations requiring an ED visit and/or hosp occurring from the start of IP up to the Week 52 visit, including exacerbations reported after early discontinuation from IP by participants who remained in the study, were included in the analysis. This analysis was performed on the mITT population.
From randomization to Week 52
Change From Baseline in Mean Total St. George's Respiratory Questionnaire (SGRQ) Score
Time Frame: Baseline and Week 52
The SGRQ for COPD is a 40-item questionnaire derived from the original SGRQ , designed to measure health impairment by addressing the frequency of respiratory symptoms and current state of the participant. SGRQ Total Scores range from 0 to 100 with higher scores indicating worse health-related quality of life and reductions indicating improvement. The Baseline value will be the last measurement collected prior to the first dose of investigational product.Change from Baseline is calculated as the post-dose visit value minus the Baseline value. Mean change from Baseline in SGRQ score at Week 52 has been presented.
Baseline and Week 52
Change From Baseline in Mean COPD Assessment Test (CAT) Score
Time Frame: Baseline and Week 52
The CAT is an 8-item questionnaire developed for use in routine clinical practice to measure the health status of participants with COPD. Each question is assessed on a 6-point scale ranging from 0 (no impairment) to 5 (maximum impairment) with the CAT score ranging from 0-40. Higher scores indicate greater disease impact with reductions indicating improvement. The Baseline value will be the last measurement collected prior to the first dose of investigational product. Change from Baseline is calculated as the post-dose visit value minus the Baseline value. Mean change from Baseline in CAT score at Week 52 has been presented.
Baseline and Week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 24, 2014

Primary Completion (ACTUAL)

January 16, 2017

Study Completion (ACTUAL)

January 16, 2017

Study Registration Dates

First Submitted

April 3, 2014

First Submitted That Met QC Criteria

April 3, 2014

First Posted (ESTIMATE)

April 7, 2014

Study Record Updates

Last Update Posted (ACTUAL)

August 16, 2018

Last Update Submitted That Met QC Criteria

July 20, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD for this study will be made available via the Clinical Study Data Request site.

IPD Sharing Time Frame

IPD is available via the Clinical Study Data Request site (click on the link provided below)

IPD Sharing Access Criteria

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Disease, Chronic Obstructive

Clinical Trials on Mepolizumab

Subscribe